Kelly L. Andrzejewski DO, PhD
Kelly L. Andrzejewski
DO, PhD
Clinical Assistant Professor
Jacobs School of Medicine & Biomedical Sciences
Specialty/Research Focus
Movement Disorders
Contact Information
Patient Care
Patient Care
This faculty member is affiliated with UBMD, practicing physicians who are also professors in the Jacobs School.
View this physician on UBMDProfessional Summary:
I am a neurologist with special training in the treatment of movement disorders. In an outpatient setting, I care for patients with Parkinson’s disease, Huntington’s disease (HD), generalized and focal dystonia, essential tremor, Tourette’s syndrome, tardive dyskinesia, progressive supranuclear palsy, multiple systems atrophy, ataxias, and other movement disorders. I perform botulinum toxin injections for dystonia, blepharospasm and sialorrhea. I also care for patients with neurological disorders when they have been admitted to Buffalo General Medical Center (BGMC).
I am the Director of the Deep Brain Stimulation (DBS) program at the University at Buffalo. I evaluate patients to determine if DBS surgery will help alleviate their neurological symptoms; if it will, I perform intraoperative electrophysiology monitoring during DBS lead placement. I also program patients’ neurostimulator system following DBS surgery. I collaborate closely with my neurosurgical colleagues from UBMD Neurosurgery and DBS team members to provide an integrated treatment plan for each of my patients.
I am the Director of the University at Buffalo Huntington Disease Society of America (HDSA) Center of Excellence that provides full care for individuals with HD. HD is a dominantly inherited genetic disease: each child of a parent with HD has a 50 percent chance of inheriting the disease from their affected parent. Our HDSA Center of Excellence ensures that patients receive a team- and family-centered approach to their care—i.e., in addition to the medical care patients receive from me, they and their families receive support from a social worker and a genetic counselor. We also offer counseling and genetic testing for individuals that are at risk of having HD. To set up an appointment in the University at Buffalo Huntington‘s Disease Clinic or learn more information about predictive testing for individuals at risk for HD please contact our scheduler at 716-932-6080.
I also teach residents and medical students in clinic and on the general neurology service at BGMC.
Education and Training:
- Fellowship, University of Rochester (2016)
- Residency, University Hospitals Case Medical Center (2014)
- Internship, University Hospitals Case Medical Center (2011)
- DO, Michigan State University (2010)
- PhD, Michigan State University (2008)
- BS, Canisius College (2002)
Journal Articles:
- Guttuso T, Andrzejewski KL, Lichter DG, Andersen JK, Guttuso, Jr. TJ. (2019) Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci (Jul), 402: 121-130.
- Banno H, Andrzejewski KL, McDermott MP, Murphy A, Majumder M, de Blieck EA, Auinger P, Cudkowicz ME, Atassi N. (2017) Analysis of Participant Withdrawal in Huntington Disease Clinical Trials. J Huntingtons Dis (Jan), 6(2): 149-156.
- Andrzejewski KL, Dowling AV, Stamler D, Felong TJ, Harris DA, Wong C, Cai H, Reilmann R, Little MA, Gwin JT, Biglan KM, Dorsey ER. (2016) Wearable Sensors in Huntington Disease: A Pilot Study. J Huntingtons Dis (Jun), 5(2): 199-206.
- Simkins TJ, Janis KL, McClure AK, Behrouz B, Pappas SS, Lehner A, Kaminski NE, Goudreau JL, Lookingland KJ, Kaplan BL, Andrzejewski KL. (2012) Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout mice. J Neuroimmune Pharmacol (Sep), 7(3): 533-538.
- Lehner A, Johnson M, Simkins T, Janis K, Lookingland K, Goudreau J, Rumbeiha W, Andrzejewski KL. (2011) Liquid chromatographic-electrospray mass spectrometric determination of 1-methyl-4-phenylpyridine (MPP+) in discrete regions of murine brain. Toxicol Mech Methods (Mar), 21(3): 171-182.
- Janis KL, Brennan RT, Drolet RE, Behrouz B, Kaufman SK, Lookingland KJ, Goudreau JL, Andrzejewski KL. (2008) Effects of sildenafil on nigrostriatal dopamine neurons in a murine model of Parkinson's disease. J Alzheimers Dis (Sep), 15(1): 97-107.
- Pappas SS, Behrouz B, Janis KL, Goudreau JL, Lookingland KJ, Andrzejewski KL. (2008) Lack of D2 receptor mediated regulation of dopamine synthesis in A11 diencephalospinal neurons in male and female mice. Brain Res (Jun), 1214: 1-10.